di Giancarlo Nicoli
Mar
1
My latest SeekingAlpha:
Regional Management: Underfollowed And Undervalued
Tags:
Investimenti, Regional Management, RM, Seeking Alpha, Value Invesingdi Giancarlo Nicoli
Jan
17
Laid-Back Portfolio Adds Vanguard Natural Resources
Filed Under Investimenti, SeekingAlpha Articles | Leave a Comment
My latest Seeking Alpha:
http://seekingalpha.com/article/1117741-laid-back-portfolio-adds-vanguard-natural-resources
Tags:
AGNC, BBEP, Dividend Ideas, Dividend Quick Picks & Lists, Dividends & Income, FSC, Income Investing Strategy, Investimenti, Investing for Income, MPW, NYBC, SBRA, Seeking Alpha, SeekingAlpha Articles, STON, TCAP, VNRdi Giancarlo Nicoli
Nov
15
My latest Seeking Alpha:
http://seekingalpha.com/article/1010641-laid-back-portfolio-adds-stonemor
Tags:
AGNC, BBEP, Dividend Ideas, Dividend Quick Picks & Lists, Dividends & Income, FSC, Income Investing Strategy, Investimenti, Investing for Income, MPW, NYBC, SBRA, Seeking Alpha, SeekingAlpha Articles, STON, TCAPdi Giancarlo Nicoli
Apr
5
Another Favorable Look At Business Development Companies
Filed Under Investimenti, SeekingAlpha Articles | Leave a Comment
My latest Seeking Alpha:
http://seekingalpha.com/article/480131-another-favorable-look-at-business-development-companies
Tags:
ACAS, Asset Management, Dividend Ideas, Dividend Quick Picks & Lists, FSC, FULL, Income Investing Strategy, Investimenti, Investing for Income, PNNT, PSEC, Seeking Alpha, SeekingAlpha Articles, SLRC, TCAP, TICCdi Giancarlo Nicoli
Mar
24
My latest Instablog on Seeking Alpha:
Today’s Instablogis more like a call for readers’ stories.
I got a comment a while back from Lawrence Marc-Aurele:
Provenge is only given to prostate cancer (PC) patients who are advanced and in poor health. The goal should be to give it to men who have PC, but want to avoid becoming advanced. Most men with PC, if given an option, would want to try something like Provenge first, before doing surgery, ADT, radiation or chemo. Requiring men to be in bad shape before they even qualify for a clinical trial is counter-productive. Men are dying and/or suffering side effects from harsh treatments. No one is talking about this. I was am because 3 years ago, I was denied access to a Provenge clinical trial in NYC on the basis of ‘being too healthy’. 4 operations in the past year, plus a PSA of 150 tell me I may die waiting for Provenge. Many men are in the same boat. Neither Dendreon or the FDA seem to care.
Also today on Investor Village (IV) a poster said:
The only thing I can say with exact knowledge is that if you’re dealing with PC, Provenge is the best solution compared to the existing other potential treatments. My urologist would like to put me on Provenge but I’m not sick enough yet. I guess when I’m closer to death I’ll be allowed to get Provenge. Thanks FDA. I will probably cost $300,000 to my insurance company before I can be put on Provenge. Great deal for both my insurance company and myself.
We do know that Provenge is an immunotherapy. As Provenge trains one’s immune system to deal with Prostate Cancer (PC), you would want to administer it when the immune system is healthier. I believe it is reasonable to assume that the earlier it is administered, the better.
Do you have stories, like the two above, that you do want to share? I’d like to write an article with your help.
Disclosure: I am long DNDN.
Additional disclosure: I am long DNDN and will not alter my position within 72 hours of the time of publication of this article.
Tags:
Dendreon, Provenge, Seeking Alphadi Giancarlo Nicoli
Feb
4
Sustainable Picks For Laid-Back Dividend Investing
Filed Under Investimenti, SeekingAlpha Articles | Leave a Comment
My latest Seeking Alpha:
Sustainable Picks For Laid-Back Dividend Investing
Tags:
AGNC, Dividend Ideas, Dividend Quick Picks & Lists, FSC, Investimenti, Investing for Income, Seeking Alpha, SeekingAlpha Articles, VGRdi Giancarlo Nicoli
Feb
3
Giancarlo Nicoli adheres to Seeking Alpha’s Gold Standard Compliance
Filed Under Investimenti | Leave a Comment
Giancarlo Nicoli adheres to
Seeking Alpha’s Gold Standard Compliance
1. Author qualification
* Authors attest that they have never been prosecuted on any securities-related issue, that they have never been barred from the securities industry, or convicted of a felony. (If you cannot agree to point 1 above but would still like to become a Seeking Alpha contributor, please contact us at contributors@seekingalpha.com).
2. Disclosure of positions and intention to purchase securities
* Authors agree to disclose the existence at the time of writing of a long or short position (including stocks, options or other instruments) in any stock mentioned in an article. The suggested form of disclosure is to add the disclosure in the following format to the bottom of articles: “Disclosure: Long GOOG at time of writing”. If the author has no position in stocks mentioned, that should be indicated in the following format: “Disclosure: No position in stocks mentioned’
* Authors may not write about a stock with the intention to boost or reduce the stock’s price and sell (or buy) the stock into the resulting strength or weakness.
* If the author intends at the time of writing to sell or buy a stock within three days of publication of an article that discusses that stock, the author must disclose this.
3. Disclosure of business relationships and conflicts of interest; no Investor Relations professionals
* Authors agree to disclose in the footer of posts any and all personal, material relationships with companies whose stocks they write about, or personal, material relationships with parties that stand to gain from the viewpoint they are outlining. Examples: authors must disclose if they are employed by a company whose stock they are writing about; perform consulting for a company they write about; receive paid advertising revenue or any other form of sponsorship fee from a company they write about. This applies to narrow asset classes as well. For example, if an author is paid to promote a gold dealer, that must be disclosed in any article about gold.
* Authors may not work in the field of investor relations. We will not accept articles from authors who work in the field of investor relations, even if the article focuses on companies with which the author has no business relationship.
4. Non-Infringement of Copyright
* Authors attest that any articles submitted for publication to Seeking Alpha do not infringe upon the rights of any other party. If other sources are quoted, the source must be clearly cited (and linked to when possible) and the quote must be within the parameters of Fair Use.
5. Commitment to Accuracy
* Authors certify that all facts in articles submitted to Seeking Alpha are accurate to the best of his/her knowledge.
6. Author’s websites, promotion and other material
* Authors’ web sites, which Seeking Alpha will be asked to link to, may not contain any illegal material, racism or pornography.
* Authors must substantiate publicly any claims regarding their investment track records that are stated on their web sites, if such a claims are made.
* Authors may not make any guarantees or explicit predictions regarding the market performance that subscribers to their paid newsletters or other services can expect.
* Authors’ web sites must not contain sensationalist language about stocks, e.g. “rocket” or “set to soar.”
7. Anonymity and accountability
* Authors agree to provide their real names, phone number and an active email to Seeking Alpha, even if they intend their articles to be published anonymously under a pseudonym.
Tags:
Investimenti, Seeking AlphaSeeking Alpha Gold Certification
Creative Common License
